Literature DB >> 3088218

Tocainide and myotonic dystrophy.

R Harries-Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3088218     DOI: 10.1007/bf00314435

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

1.  Tocainide associated agranulocytosis.

Authors:  K Volosin; R M Greenberg; A J Greenspon
Journal:  Am Heart J       Date:  1985-06       Impact factor: 4.749

2.  Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias.

Authors:  W Ryan; R Engler; M LeWinter; J S Karliner
Journal:  Am J Cardiol       Date:  1979-02       Impact factor: 2.778

3.  Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

Authors:  K Ricker; A Haass; R Rüdel; R Böhlen; H G Mertens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-03       Impact factor: 10.154

4.  Confusion and paranoia associated with oral tocainide.

Authors:  C W Clarke; E O el-Mahdi
Journal:  Postgrad Med J       Date:  1985-01       Impact factor: 2.401

5.  Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Authors:  U Mielke; A Haass; S Sen; W Schmidt
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

6.  Safety evaluation of tocainide in the American Emergency Use Program.

Authors:  H R Horn; Z Hadidian; J L Johnson; H G Vassallo; J H Williams; M D Young
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.